
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Esophageal Squamous Papilloma and Papillomatosis: Current Evidence of HPV Involvement and Malignant Potential</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Esophageal Squamous Papilloma and Papillomatosis: Current Evidence of HPV Involvement and Malignant Potential</strong></summary>
            <div>
                <ul><li>Journal: Cancers (Basel). 2025 Jul 20;17(14):2404. doi: 10.3390/cancers17142404</li><li>PMCID: PMC12293905; PMID: 40723286</li><li>Keywords: Esophageal squamous papilloma, esophageal papillomatosis, human papillomavirus (HPV), endoscopy, malignant potential, surveillance</li><li>Summary: Rare esophageal lesions (ESP/papillomatosis) traditionally benign, but emerging evidence suggests possible association w/ high-risk HPV (hr-HPV) infection &amp; potential malignant progression risk.</li><li>Review covers pathogenesis, clinical features, diagnostic approaches, management strategies, focusing on HPV role &amp; advanced endoscopic imaging.</li><li>Further research urgently needed to clarify oncogenic potential &amp; optimize surveillance/treatment protocols.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of HPV infections typically clear spontaneously?</li><li>2. Which two high-risk HPV genotypes are most frequently associated with high-grade dysplasia and cancer?</li><li>3. What is the reported prevalence range of Esophageal Squamous Papilloma (ESP) during esophagogastroduodenoscopy (EGD)?</li><li>4. In cases of esophageal squamous papillomatosis, what percentage of patients in a recent review developed ESCC?</li><li>5. According to the JES classification, what do Type B microvessels (with severe irregularity) indicate in superficial ESCC?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction to HPV-Related Esophageal Lesions</strong></summary>
            <div>
                <ul><li>HPV: established oncogenic agent in cervical, anogenital, oropharyngeal cancers.</li><li>Increasing attention on HPV&#x27;s role in esophageal squamous pathology.</li><li>Esophageal squamous papilloma (ESP) &amp; papillomatosis: rare, but growing evidence links them to hr-HPV &amp; risk of dysplasia/malignant transformation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Human Papillomavirus (HPV) Infection</strong></summary>
            <div>
                <ul><li>HPV: small, non-enveloped, double-stranded DNA virus; infects basal keratinocytes.</li><li>Most prevalent sexually transmitted infection: lifetime risk ≈ 50% for men &amp; women.</li></ul>
                
        <details>
            <summary><strong>Biology &amp; Oncogenesis</strong></summary>
            <div>
                <ul><li>Risk factors: high # lifetime sexual partners, early sexual activity, co-infections (e.g., HIV).</li><li>Children transmission: hand-to-mouth contact, perinatal (vaginal delivery), less commonly in utero.</li><li>Esophageal transmission mechanisms: unclear; hypothesized neonatal contamination, sexual contact, direct mucosal exposure.</li></ul>
                
        <details>
            <summary><strong>Sexual Behavior &amp; Oral HPV Risk</strong></summary>
            <div>
                <ul><li>Certain sexual behaviors → ↑ risk of HPV transmission to upper aerodigestive tract.</li><li>Early sexual activity, multiple partners, unprotected oro-genital contact, male-to-male intercourse.</li><li>Mistry et al. [16]: oral sex → significant association w/ oral/oropharyngeal HPV (p = 0.0038) in men who have sex with men.</li><li>Dalla Torre et al. [17]: high # vaginal (p = 0.0001) &amp; oral (p &lt; 0.0001) sexual partners → significant association w/ oral HPV positivity in young adults (18-30 yrs).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HPV Infection Outcomes</strong></summary>
            <div>
                <ul><li>Most HPV infections: asymptomatic; ≈90% clear spontaneously.</li><li>Persistent infection (≈10% cases) → significantly ↑ risk malignant transformation.</li><li>Immunocompetent adults: transient mucosal infections resolve within 8–14 months; persistence &gt; 24 months rare (except immunosuppressed/HIV+).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HPV Genotypes &amp; Carcinogenesis</strong></summary>
            <div>
                <ul><li>&gt;100 HPV genotypes identified: classified as high-risk (hr-HPV) or low-risk.</li><li>IARC carcinogenic: 12 hr-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59).</li><li>&#x27;Probably&#x27;/&#x27;possibly&#x27; carcinogenic: 8 additional types (26, 53, 66, 67, 67, 70, 73, 82).</li><li>Most frequent w/ high-grade dysplasia/cancer: HPV types 16 &amp; 18.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Malignant Progression Mechanism</strong></summary>
            <div>
                <ul><li>Persistent hr-HPV infection → viral entry via microabrasions → basal layer epithelium.</li><li>Key event: viral DNA integration into host genome → overexpression of viral oncoproteins E6 &amp; E7.</li><li>E6: promotes p53 degradation.</li><li>E7: inactivates retinoblastoma protein (pRb) → ↑ p16INK4a (p16).</li><li>p16: surrogate marker for oncogenic HPV activity (in cervical/oropharyngeal cancer).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>HPV Detection Methods</strong></summary>
            <div>
                <ul><li>Common methods: Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC) for p16.</li><li>PCR: high sensitivity &amp; specificity for HPV DNA.</li><li>ISH: less sensitive, but provides spatial context by localizing viral DNA within tissue.</li><li>IHC for p16: widely accepted surrogate marker for transcriptionally active HPV in cervical/oropharyngeal cancer.</li></ul>
                
        <details>
            <summary><strong>Limitations in Esophageal Pathology</strong></summary>
            <div>
                <ul><li>In Esophageal Squamous Cell Carcinoma (ESCC): p16 expression not consistently correlated w/ HPV DNA.</li><li>∴ p16 not reliable surrogate marker for HPV-driven oncogenesis in ESCC.</li><li>Most frequent detection methods for HPV in esophageal tissue: PCR &amp; ISH.</li><li>Reported HPV detection rates: 10% to 80% (varies by technique, geography, patient selection); PCR generally higher sensitivity than ISH.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histopathological Features</strong></summary>
            <div>
                <ul><li>Koilocytic changes (nuclear enlargement, irregular membranes, perinuclear clearing) occasionally observed in HPV-related esophageal papillomas.</li><li>Not pathognomonic nor consistently present; diagnostic value ↑ w/ molecular confirmation (PCR/ISH).</li><li>Need for standardized diagnostic criteria &amp; detection protocols in future studies.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>HPV-Related Esophageal Lesions</strong></summary>
            <div>
                <ul><li>Esophageal squamous papilloma (ESP) &amp; papillomatosis are primary lesions potentially associated w/ HPV infection.</li><li>Relatively rare, but increasing attention due to suspected viral etiology &amp; potential for malignant transformation.</li></ul>
                
        <details>
            <summary><strong>Esophageal Squamous Papilloma (ESP)</strong></summary>
            <div>
                <ul><li>Rare, benign epithelial tumor; first described 1959.</li><li>Prevalence: 0.01% to 0.45% during EGD; pediatric prevalence ≈ 0.08%.</li><li>Prevalence appears ↑: Pantham et al. reported rise from 0.13% (2000) to 0.57% (2013).</li></ul>
                
        <details>
            <summary><strong>Demographics &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Median age: 49-52 years; some reports indicate slight female predominance.</li><li>More common among White patients [41]. Recent study: younger (median 52 yrs, p=0.021), more African American (p&lt;0.001), balanced M:F ratio [3].</li><li>Most ESPs: asymptomatic, incidentally discovered during EGD.</li><li>Symptoms (when present): non-specific (dyspepsia, heartburn, epigastric discomfort, dysphagia); often related to underlying esophageal conditions (reflux, inflammation).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Location &amp; Endoscopic Appearance</strong></summary>
            <div>
                <ul><li>Most common location: middle &amp; distal thirds of esophagus; can occur throughout tract.</li><li>Endoscopic appearance: small (2–6 mm), solitary, whitish-pink, wart-like exophytic lesion; mostly pedunculated/semi-pedunculated; well-demarcated margins.</li><li>Virtual chromoendoscopy (NBI, BLI) improve diagnostic accuracy.</li><li>Triad: exophytic growth, wart-like projections, crossing surface vessels → PPV 88% [37].</li><li>NBI often reveals brownish vascular lines (fibrovascular core).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histology &amp; Classification</strong></summary>
            <div>
                <ul><li>Histologically: finger-like projections of squamous epithelium overlying a fibrovascular core.</li><li>Larger lesions (&gt;10 mm), clustered lesions, or diffuse involvement: classified as esophageal squamous papillomatosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pathogenesis</strong></summary>
            <div>
                <ul><li>Exact pathogenesis uncertain; two major hypotheses: chronic mucosal irritation &amp; HPV infection.</li><li>Irritation-related factors: GERD, mechanical trauma (sclerotherapy, metal stent), alcohol &amp; tobacco use.</li><li>GERD supported by frequent distal esophageal localization; however, no studies report reflux-associated histologic changes in non-papillomatous mucosa.</li></ul>
                
        <details>
            <summary><strong>HPV Association in ESP</strong></summary>
            <div>
                <ul><li>First suggested by Syrjanen et al. in 1982.</li><li>HPV detection rates in ESPs: 10% to 80% [32,35,39,47,51,52]; some studies failed to detect HPV [3,36,53,54,55].</li><li>Low-risk HPV types 6 &amp; 11 most commonly detected.</li><li>Takeshita et al.: HPV DNA (type 6) in 10.5% of samples [35].</li><li>High-risk HPV also identified: Odze et al.: HPV in 50% of ESPs, type 16 most frequent [47].</li><li>Tiftikçi et al.: 19% of ESPs HPV-positive; 3 cases type 6, 4 cases types 16, 18, 31, 81 (oncogenic) [52].</li><li>Bohn et al.: ≈80% of ESPs HPV-positive, mainly low-risk types; ACISH sensitivity comparable to PCR [32].</li><li>Conclusion: Evidence increasingly supports HPV-ESP association; true prevalence may be underestimated due to limited genotype screening.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Squamous Papillomatosis</strong></summary>
            <div>
                <ul><li>Even more exceptional condition than solitary ESPs; literature scarce, primarily case reports.</li><li>First described case: 1977, 3.5-year-old boy w/ pyriform sinus papilloma.</li><li>Exhibits distinct clinical &amp; pathological features from solitary ESPs.</li></ul>
                
        <details>
            <summary><strong>Epidemiology &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Recent review (Li et al. [2], 53 cases): mean age ≈ 46.8 years; no significant sex-based or geographic differences.</li><li>Frequently presents with symptoms (unlike solitary ESPs).</li><li>Dysphagia: most common complaint (32/53 cases), followed by heartburn, weight loss, epigastric discomfort, dyspepsia.</li><li>Symptoms due to extent &amp; confluence of lesions, reflecting greater mucosal &amp; inflammatory burden.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis &amp; Endoscopic Appearance</strong></summary>
            <div>
                <ul><li>Diagnosis via EGD: multiple small, whitish or pinkish projections; smooth or slightly rough surface; sessile or pedunculated; tightly clustered pattern [57].</li><li>Lesion size: 1 to 15 mm [58]; number may be too high to count.</li><li>Involvement: limited to part of esophagus (usually middle/distal thirds) or entire tract, sometimes causing strictures [2].</li><li>Advanced imaging techniques: NBI w/ magnification [57,59,60], Lugol’s iodine staining [61,62], endoscopic ultrasound (EUS) [63,64] are valuable tools.</li><li>Histologic confirmation essential: multiple finger-like projections of hyperplastic squamous epithelium over fibrovascular cores [57].</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pathogenesis &amp; HPV Involvement</strong></summary>
            <div>
                <ul><li>Pathogenesis unclear, likely mirrors ESPs.</li><li>Chronic mucosal irritation: major factor (especially GERD, chemical irritants like tobacco/alcohol, mechanical injuries).</li><li>Animal studies: gastroesophageal &amp; duodenal reflux can induce papillomatosis [65,66,67].</li><li>Evidence for HPV involvement: limited. Li et al. review [2]: 29/53 cases tested, 11 (37.9%) positive.</li><li>12 HPV genotypes identified; low-risk types 6 &amp; 11 in 6 cases.</li><li>Notably, 4 patients positive for HPV 16 (high-risk), half of whom developed esophageal cancer [68,69].</li><li>True prevalence of HPV may be underestimated due to limited genotype screening &amp; lack of testing in many reports.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Advanced Endoscopic Techniques for Lesion Characterization</strong></summary>
            <div>
                <ul><li>Endoscopy: central role in detection, characterization, surveillance of HPV-related esophageal squamous lesions.</li><li>Critical to distinguish benign from dysplastic or superficially invasive ESCC for appropriate management.</li><li>Standard high-definition white light endoscopy (WLE): first-line tool for location, morphology, size, extent.</li></ul>
                
        <details>
            <summary><strong>Advanced Imaging Modalities</strong></summary>
            <div>
                <ul><li>Virtual chromoendoscopy (NBI, BLI) &amp; dye-based chromoendoscopy (Lugol’s iodine) → superior diagnostic performance for early neoplastic changes, especially superficial ESCC.</li><li>Enhance ability to differentiate benign HPV-related lesions from those w/ dysplastic or malignant features [70].</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Lugol’s Chromoendoscopy</strong></summary>
            <div>
                <ul><li>Well-established technique for early detection of squamous neoplasia.</li><li>Iodine solution selectively stains glycogen-rich normal squamousepithelium dark brown.</li><li>Dysplastic or neoplastic tissue: glycogen depletion → unstained or hypocolored (&#x27;Lugol-voiding lesions&#x27;).</li><li>Useful in ESP/papillomatosis: hypopigmented/unstained regions may indicate dysplasia/carcinoma.</li><li>Case reports: successful application in delineating complex lesions &amp; guiding targeted biopsies [57,61,62,70,72].</li><li>Caution: glycogen-depleted metaplastic epithelium (e.g., Barrett’s) may also appear Lugol-negative, mimicking dysplasia.</li><li>Correlation w/ virtual chromoendoscopy &amp; targeted biopsy essential to avoid misinterpretation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Virtual Chromoendoscopy (NBI &amp; BLI)</strong></summary>
            <div>
                <ul><li>ESGE guidelines: validated alternative to Lugol’s for superficial ESCC detection; outperform WLE alone [73,74].</li><li>Enables detailed visualization of mucosal microvascular patterns, especially intrapapillary capillary loops (IPCLs).</li><li>IPCLs: appear as brownish loops on magnified NBI; show characteristic morphological alterations in dysplastic/malignant tissue.</li><li>Changes in IPCL shape, caliber, distribution → correlate w/ degree of epithelial irregularity &amp; neoplastic invasion.</li></ul>
                
        <details>
            <summary><strong>IPCL Classification System</strong></summary>
            <div>
                <ul><li>Morphological grading of vascular changes.</li><li>Types III to V: progressive dilation, tortuosity, irregularity → associated w/ high-grade dysplasia or carcinoma [75].</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>JES (Japan Esophageal Society) Classification</strong></summary>
            <div>
                <ul><li>Stratifies lesions based on IPCL features to estimate invasion depth.</li><li>Type A microvessels (w/o severe irregularity): non-neoplastic or low-grade dysplastic lesions.</li><li>Type B microvessels (w/ severe irregularity): cancerous changes.</li><li>B1: High-grade intraepithelial neoplasia or carcinoma limited to mucosa (m1/m2).</li><li>B2: Invasion into muscularis mucosae (m3) or superficial submucosa (sm1).</li><li>B3: Invasion at least into deeper submucosa (≥sm2) [76,77,78].</li><li>Overall accuracy of type B vessels for predicting invasion depth: &gt;90% [79].</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Utility in Papillomas/Papillomatosis</strong></summary>
            <div>
                <ul><li>No specific studies on virtual chromoendoscopy differentiating papillomas/papillomatosis from dysplasia/ESCC.</li><li>Case reports suggest utility: benign papillomas → typically regular vascular patterns or subtle brownish vascular lines [37].</li><li>Dysplastic/malignant transformation → irregular, dilated IPCLs.</li><li>Supports NBI value in improving diagnostic precision [57,59,60,72].</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Comprehensive Endoscopic Strategy</strong></summary>
            <div>
                <ul><li>Integration of high-definition WLE, virtual chromoendoscopy (NBI/BLI), &amp; Lugol’s staining → comprehensive approach.</li><li>Improves lesion characterization, enhances risk stratification, guides management decisions.</li><li>Especially valuable in HPV-related esophageal lesions w/ potential dysplastic/early neoplastic foci, particularly extensive papillomatosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histologic Examination: Gold Standard</strong></summary>
            <div>
                <ul><li>Despite enhanced sensitivity of imaging techniques, histologic examination remains diagnostic gold standard.</li><li>Biopsy essential, especially for extensive or suspicious lesions.</li><li>Esophageal papillomatosis: multiple biopsies (typically 2-15) recommended due to potential hidden focal dysplasia.</li><li>Targeted sampling crucial for suspicious features (irregular vascular patterns on NBI/BLI, hypopigmented areas on Lugol’s) → more likely to harbor neoplasia [2].</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recurrence and Malignant Potential</strong></summary>
            <div>
                <ul><li>ESP &amp; papillomatosis generally benign, but concerns about recurrence &amp; malignant transformation, especially w/ hr-HPV.</li><li>Conclusive evidence lacking due to rarity &amp; limited long-term data.</li><li>Oncogenic HPV genotypes (16, 18) identified in benign lesions &amp; ESCC specimens.</li><li>Meta-analyses: statistically significant association between HPV infection &amp; ESCC (OR 2.7-3.8) [30,80,81,82].</li><li>Suggests potential HPV-related continuum in esophageal pathology.</li><li>Clearer understanding of recurrence/progression risk essential for surveillance/therapy.</li></ul>
                
        <details>
            <summary><strong>Esophageal Squamous Papilloma (ESP)</strong></summary>
            <div>
                <ul><li>Generally benign, managed w/ complete endoscopic resection.</li><li>Evidence on recurrence &amp; malignant progression scarce due to rarity &amp; limited follow-up [43].</li></ul>
                
        <details>
            <summary><strong>Recurrence After Resection</strong></summary>
            <div>
                <ul><li>Most cases: no recurrence after removal of benign, non-dysplastic lesions [3,34,36,83].</li><li>French study: 3.4% recurrence rate after 1st ESP resection, 0% after 2nd [34].</li><li>Possible residual disease vs. true recurrence: some lesions not fully excised initially.</li><li>Ahmad et al. [3]: 17/18 patients w/ follow-up EGD showed no recurrence after ESP resection.</li><li>Follow-up adherence suboptimal (&lt;50% in all studies) → hinders definitive conclusions.</li><li>Current evidence: recurrence rare or possibly absent in benign, non-dysplastic ESPs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Malignant Potential</strong></summary>
            <div>
                <ul><li>Controversial; most lesions non-neoplastic, but isolated reports of progression to ESCC.</li><li>D’Huart et al. [34]: 1 case (1.3%) of malignant transformation among 78 patients; SCC developed at site of resected low-grade dysplastic ESP 2 yrs prior (75-year-old male, smoking/alcoholic liver disease).</li><li>Another case: 1.5 cm ESP at EGJ progressed to in situ carcinoma over 2 yrs (44-year-old female, no risk factors) [84].</li><li>Ahmad et al. [3]: 1/66 patients developed ESCC during follow-up (no known risk factors).</li><li>Cases support potential for malignant transformation; lack of prospective studies &amp; limited follow-up preclude defining specific timeframe.</li><li>HPV implicated as potential contributor; however, HPV not detected in reported ESP-associated ESCC cases (likely due to testing limitations/restricted genotypes) [3,34,84].</li><li>Detection of high-risk genotypes in ESPs supports hypothesis of potential progression pathway [39,52].</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Squamous Papillomatosis</strong></summary>
            <div>
                <ul><li>Higher risk of malignant transformation than solitary ESPs.</li><li>Macroscopic features (large size, multiplicity, confluence, circumferential distribution) → proposed indicators of malignancy risk [34].</li><li>Extensive disease: poses oncologic &amp; quality of life concerns.</li></ul>
                
        <details>
            <summary><strong>Malignant Transformation Risk</strong></summary>
            <div>
                <ul><li>Li et al. review [2] (53 cases): 12 patients (22.6%) developed ESCC [61,63,64,68,69,85,86,87,88,89,90,91].</li><li>3 cases: varying degrees of dysplasia within lesions [62,92,93].</li><li>2 additional cases: low-grade dysplasia in patients w/ dysphagia [70,72].</li><li>Findings support papillomatosis as premalignant condition.</li><li>Malignant transformation: seems to occur within months to few years after diagnosis, especially w/ extensive mucosal involvement &amp; hr-HPV infection.</li><li>Precise estimates limited by scarcity of long-term follow-up &amp; reliance on case reports.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HPV Involvement in Malignant Transformation</strong></summary>
            <div>
                <ul><li>HPV infection implicated; among 12 cases progressing to ESCC, only 2 confirmed HPV infection [68,69].</li><li>Among 5 dysplastic cases, only 1 tested positive for HPV [93].</li><li>All 3 HPV-positive cases: genotype HPV-16.</li><li>Data suggest possible oncogenic role, but association not consistent; additional cofactors (e.g., chronic GERD) may be involved.</li><li>Inconsistent HPV testing &amp; limited genotype panels hinder interpretation.</li><li>Detection of high-risk HPV in cases progressing to dysplasia/carcinoma suggests possible contributory role.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recurrence</strong></summary>
            <div>
                <ul><li>Limited data. Li et al. review [2]: only 9/30 patients (30%) treated w/ medical, endoscopic, or surgical approaches remained recurrence-free (follow-up: 3 months to 2 years).</li><li>Illustrative case: diffuse HPV 16-positive papillomatosis w/ HCV co-infection; underwent Ivor Lewis esophagectomy, but recurrence @ gastroesophageal anastomosis 1 yr later [93].</li><li>Underscores importance of long-term surveillance &amp; individualized therapeutic planning.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion on Papillomatosis Risk</strong></summary>
            <div>
                <ul><li>Rare, but carries measurable risk of malignant transformation &amp; recurrence.</li><li>Involvement of high-risk HPV genotypes suggests possible progression pathway (benign epithelial proliferation → malignancy), similar to other HPV-associated conditions.</li><li>Close clinical follow-up, personalized management, &amp; regular endoscopic monitoring essential for early detection of progression.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment and Surveillance</strong></summary>
            <div>
                <ul><li>Potential for dysplasia &amp; malignant progression → complete removal of ESPs &amp; papillomatosis when feasible [2,3].</li><li>Specific clinical guidelines lacking due to rarity.</li><li>Available data support proactive approach to treatment &amp; surveillance.</li></ul>
                
        <details>
            <summary><strong>Esophageal Squamous Papilloma (ESP)</strong></summary>
            <div>
                <ul><li>Low risk of malignant transformation; complete endoscopic removal recommended.</li><li>Management tailored to lesion size, morphology, histology, patient risk factors.</li></ul>
                
        <details>
            <summary><strong>Treatment Modalities</strong></summary>
            <div>
                <ul><li>Small (≤5 mm), pedunculated/sessile lesions w/o dysplasia: typically managed w/ biopsy forceps [94,95,96,97].</li><li>Larger lesions (&gt;5 mm): may require snare polypectomy or endoscopic mucosal resection (EMR) [40,84].</li><li>Endoscopic submucosal dissection (ESD): reserved for lesions suspicious for superficial ESCC (JES types A, B1, B2), especially for en bloc resection &amp; accurate histologic staging [78,84].</li><li>Radiofrequency ablation (RFA): reported as potential treatment in selected cases [98]; minimally invasive alternative for small lesions, but lacks histologic samples.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Post-Treatment Evaluation</strong></summary>
            <div>
                <ul><li>Histopathological evaluation: essential for diagnosis confirmation &amp; exclusion of dysplasia/carcinoma.</li><li>Molecular testing for HPV: consider in lesions w/ atypical features or dysplasia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance</strong></summary>
            <div>
                <ul><li>Individualized.</li><li>Close endoscopic monitoring: for larger lesions, dysplasia, superficial carcinoma, or high-risk HPV positivity.</li><li>Routine surveillance not required: for small, non-dysplastic, HPV-negative lesions completely removed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Squamous Papillomatosis</strong></summary>
            <div>
                <ul><li>Higher malignant potential than solitary papillomas, especially in extensive/multifocal disease.</li><li>Treatment aims: eradicate lesions, relieve symptoms (e.g., dysphagia), prevent malignant transformation.</li></ul>
                
        <details>
            <summary><strong>Treatment Modalities</strong></summary>
            <div>
                <ul><li>Endoscopic modalities: argon plasma coagulation (APC), radiofrequency ablation (RFA) [99,100], cryotherapy [101,102], photodynamic therapy (PDT) [86].</li><li>All 4 techniques: demonstrated efficacy in lesion treatment &amp; potential prevention of malignant transformation.</li><li>EMR [45] or ESD [70]: for localized or suspicious lesions; ESD offers en bloc resection &amp; improved histologic assessment (dysplasia/high-risk features) [78].</li><li>Esophagectomy: indicated in select cases w/ malignant transformation or failure of endoscopic therapy [63,68,69,85,87,88].</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Post-Treatment Evaluation</strong></summary>
            <div>
                <ul><li>Histologic &amp; virologic assessment post-resection: crucial.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance</strong></summary>
            <div>
                <ul><li>Risk-adapted: considers lesion extent, HPV status, histological findings, patient factors.</li><li>Chromoendoscopy during follow-up: aids detection of recurrent or progressing lesions.</li><li>Conservative management w/ periodic monitoring: reasonable in absence of dysplasia or high-risk HPV; no standardized protocols exist.</li><li>Multidisciplinary evaluation &amp; individualized follow-up: key to optimal long-term outcomes.</li><li>Otolaryngologic assessment: consider to rule out synchronous laryngeal/tracheal involvement (especially pediatric patients, extensive/recurrent disease).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusions</strong></summary>
            <div>
                <ul><li>ESP &amp; esophageal squamous papillomatosis: rare epithelial lesions; etiology, natural history, optimal management poorly defined.</li><li>Possible etiological role of HPV infection: low-risk genotypes w/ benign lesions, high-risk genotypes w/ dysplastic/malignant transformation.</li><li>Heterogeneity in study design, limited HPV genotyping, non-standardized detection methods → prevent definitive conclusions on HPV&#x27;s true oncogenic role.</li><li>Malignant transformation infrequent, but multifocality, lesion size, dysplasia, high-risk HPV positivity → may warrant closer surveillance.</li><li>Complete endoscopic resection: treatment of choice; histopathological &amp; virological assessment guide further management.</li><li>Prospective, standardized studies needed to clarify natural history &amp; optimize diagnostic/therapeutic algorithms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
